VITAMIN D IN HEALTH AND DISEASE: Beyond Minerals and Parathyroid Hormone: Role of Active Vitamin D in End‐Stage Renal Disease
Authors:
- 19 July 2005
- journal article
- review article
- Published by Wiley in Seminars in Dialysis
- Vol. 18 (4) , 302-306
Abstract
Secondary hyperparathyroidism is a common complication of end‐stage renal disease (ESRD) that is often treated with activated forms of intravenous vitamin D. The natural course and treatment of secondary hyperparathyroidism in hemodialysis patients is punctuated by episodes of hypercalcemia, hyperphosphatemia, and increased calcium‐phosphate product, which in previous studies were linked to increased mortality. Historically these episodes have been attributed to vitamin D, leading some authorities to favor decreased vitamin D use. However, the studies that examined the impact of mineral levels and parathyroid hormone (PTH) on survival did not consistently account for vitamin D therapy itself on hemodialysis patient survival. The current review examines in detail two recent large‐scale studies of hemodialysis patients: one that demonstrated a survival advantage of paricalcitol over calcitriol and a second that demonstrated a significant survival advantage of any intravenous vitamin D formulation versus none. In both studies, the effects were independent of mineral and PTH levels, suggesting “nontraditional” actions of vitamin D contributed to the observed survival advantage. Several of these nontraditional actions are reviewed with an emphasis on those that might impact hemodialysis outcomes.Keywords
This publication has 68 references indexed in Scilit:
- Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settingsNephrology Dialysis Transplantation, 2004
- Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidismKidney International, 2003
- A Vitamin D Analog Ameliorates Glomerular Injury on Rat GlomerulonephritisThe American Journal of Pathology, 2001
- What is the optimal regimen for vitamin D?Kidney International, 1999
- Osteodystrophy in the millenniumKidney International, 1999
- Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failureAmerican Journal of Kidney Diseases, 1998
- Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2American Journal of Kidney Diseases, 1998
- 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremiaKidney International, 1998
- Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.Journal of Clinical Investigation, 1984
- ARTERIAL CALCIFICATION AFTER VITAMIN-D THERAPY IN HYPERPHOSPHATÆMIC RENAL FAILUREThe Lancet, 1968